Aevi Genomic Medicine, Inc. (GNMX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.01), Briefing.com reports. During the same period in the previous year, the company earned ($0.29) earnings per share.
TRADEMARK VIOLATION WARNING: “Aevi Genomic Medicine, Inc. (GNMX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/03/aevi-genomic-medicine-inc-gnmx-posts-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.
In other news, Director Sol J. Barer acquired 421,032 shares of the stock in a transaction dated Tuesday, October 17th. The stock was purchased at an average cost of $1.26 per share, with a total value of $530,500.32. Following the completion of the purchase, the director now owns 1,028,032 shares in the company, valued at approximately $1,295,320.32. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael F. Cola acquired 119,047 shares of the stock in a transaction dated Tuesday, October 17th. The shares were purchased at an average cost of $1.26 per share, with a total value of $149,999.22. Following the completion of the purchase, the chief executive officer now owns 218,483 shares of the company’s stock, valued at approximately $275,288.58. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 645,910 shares of company stock valued at $811,792. Insiders own 15.20% of the company’s stock.
GNMX has been the subject of several research analyst reports. Jefferies Group LLC reissued a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research report on Monday, August 7th. Needham & Company LLC lowered their price objective on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, August 16th.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Stock Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related stocks with our FREE daily email newsletter.